Structure-based design of enzyme inhibitors and receptor ligands

Current Opinion in Drug Discovery and Development

Volumn 1, Issue 1, 1998, Pages 4-15

  Kubinyi, Hugo ^a  

^a BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002716826     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Beddell CR (Ed): The design of drugs to macromolecular targets. John Wiley & Sons, Chichester (1992).
2. Wermuth CG (Ed): The practice of medicinal chemistry.
3. Academic Press, London (1996). Modern text book on drug research, including rational drug design.
4. Laskowski RA, Hutchinson EG, Michie AD, Wallace AC, Jones ML, Thomton JM: PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends Biochem Sc/(\397) 22:488-490.
5. Greer J, Erickson JW, Baldwin JJ, Vamey MD: Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem (1994)37:1035-1054. Discusses the structure-based design of HIV protease, carbonic anhydrase and thymidylate synthase inhibitors.
6. Gubernator K, Bôhm HJ (Eds): Structure-based ligand design. Wüey-VCH, Weinheim (1998). Strategies and several success stories of structure-based and computer-assisted drug design (9 chapters; approximately 150 pages).
7. Vacca JP, Condra JH: Clinically effective HIV-1 protease inhibitors. Drug Discovery Today (1997) 2:261 -272. Overview of the rational development of the four therapeutical/y used HIV protease inhibitors saquinavir, ritonavir, indinavir and nelfinavir.
8. Werth B: The billion-dollar molecule. One company's quest for the perfect drug. Simon & Schuster, New York (1994). Fascinating novel on structure-based drug design in a start-up company. Describes the rush of engaged scientists for new immunosuppressants and HIV protease inhibitors.
9. Böhm HJ, Klebe G: What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem tnt Ed Eng/(\ 996) 35:2589-2614. Detailed review on ligand-protein interactions, binding modes of ligands, structure-based and computer-aided drug design (279 references).
10. Babine RE, Bender SL: Molecular recognition of proteinligand complexes: applications to drug design. Chem Rev (1997)97:1359-1472. Impressive, excellent and comprehensive review on the structurebased design of many different classes of enzyme inhibitors and other protein ligands (538 references).
11. Böhm HJ, Klebe G, Kubinyi H: Wirkstoffdesign. Spektrum Akademischer Verlag, Heidelberg (1996). German language book on drug research, discussing classical and modern techniques (599 pages, including about 300 pages on rational drug design methodologies and 160 pages on success stories of structure-based and computer-aided design).
12. Veerapandian P (Ed): Structure-based drug design. Marcel Dekker, New York (1997). Comprehensive overview on the structure-based design of enzyme inhibitors and other protein ligands (647 pages; 22 chapters, about 1700 references).
13. Blundell TL: Structure-based drug design. Nature (1996) 384 Supp:23-26!
14. Bohacek RS, McMartin C, Guida WC: The art and practice of structure-based drug design: a molecular modeling perspective. Meet Res Rev(1996) 16:3-50. The role of molecular modeling in structure-based design (120 references).
15. Setti EL, Micelich R: Modern drug design and lead discovery: an overview. CurrMedChem (1996) 3:317-324.
16. Martin LJ: Protein crystallography and examples of its applications in medicinal chemistry. Curr Med Chem (1996)3:419-436. Discusses protein crystallography methodology as well as applications to medicinal chemistry.
17. Seife C: Blunting nature's Swiss army knife. Science (1997)277:1602-1603 Discusses recent examples of structure-based design of proteinase inhibitors versus tryptase, cathepsin K, metalloproteinases, factor Xa, Coronavirus and Schistosoma proteases.
18. West ML, Fairtie DP: Targeting HIV-1 protease: a test of drugdesign methodologies. Trends PharmacolSei(1995) 16:67-75.
19. Prasad JVNV, Lunney EA, Para KS, Tummino PJ, Ferguson D, Hupe D, Domagala JM, Erickson JW: Nonpeptidic potent HIV1 protease inhibitors. Drug Design £>/scov(1996) 13:15-28.
20. De Lucca GV, Erickson-Viitanen S, Lam PYS: Cyclic H1V protease inhibitors capable of displacing the active site structural water molecule. Drug Discovery Today (1997) 2:6-18. Overview of the rational development of cyclic ureas as HIV protease inhibitors, starting from the publication of Lam PYS etal[59"].
21. Kempt DJ, Sham HL, Marsh KG, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, Kali WM, Ruiz L, Zhao C, Fino LM, Patterson J, Molla A, Plattner JJ, Norbeck DW: Discovery of Ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem (1998) 41:602-617.
22. Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appell K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH: Viracept (Nelfinavir mesylate, AG 1343): a potent orally bioavailable inhibitor of HIV-1 protease. J Med Chem (1997)40:3979-3985.
23. Kimball SD: Thrombin active site inhibitors. Curr Pharm Des (1995) 1:441-468.
24. Edmunds JJ, Rapundalo ST, Siddiqui MA: Thrombin and factor Xa inhibition. Annu Rep Med Chem (1996) 31:51-60.
25. Ripka WC, Vlasuk GP: Ant'rthrombotica/serine proteases. Annu Rep Med Chem (1997) 32:71-89.
26. Wiley RM, Fisher MJ: Small-molecule direct thrombin inhibitors. Exp Op/'n Ther Patents (1997) 7:1265-1282. Detailed review on thrombin inhibitors (96 structural formulas, 82 literature references and94 patent references).
27. Stubbs II MT: Structural aspects of factor Xa inhibition. Curr Pharm Des (1996) 2:543-552.
28. Maduskuie JrTP, McNamara KJ, Ru Y, Knabb RM, Stouten PFW: Rational design and synthesis of novel, potent bisphenylamidine carboxylate factor Xa inhibitors. J Med Chem (1998) 41:53-62. Convergent design of nanomolar factor Xa inhibitors, starting from the docking of small ligands into the P1 and P4 pockets and connecting these fragments with an appropriate tether.
29. Edwards PD, Veale CA: Inhibitors of human neutrophil elastase. Exp Opin Ther Patents (37) 7:17-28.
30. McKerrow JH, James MNQ (Eds): Cysteine proteases: evolution, function and inhibitor design. Persp Drug Discov Design (1996) 6:1-125. Special PD3 issue on cystelne proteinases of therapeutic interest In the treatment of cancer, viral infections, arthritis and inflammation, and parasitic infections (7 chapters, 811 references).
31. Otto HH, Schirmeister T: Cysteine proteases and their Inhibitors. Chem Rev(\Q37) 97:133-171. Comprehensive review on cysteine proteinase inhibitors (534 references).
32. Dhanaraj V, Ye Q2, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB, Rubin JR, Pavlovsky A, Humblet C, Blundell TL: Designing inhibitors of the metalloproteinase superfamily: comparative analysis of representative structures. Drug Design Discov (1996) 13:3-14.
33. Zask A, Levin Jl, Killar LM, Skotnicki JS: Inhibition of matrix metalloproteinases: structure based design. Curr Pharm Des (1996) 2:624-661. Comprehensive review on the structure-based design of collagenase, stromelysin, gelatinase, and other matrix metalloproteinase inhibitors (235 references).
34. Beckett RP, Whittaker M: Matrix metalloproteinase Inhibitors 1998. Exp Opin Ther Patents (1998) 8:259-282 Comprehensive review on the design, development and clinical evaluation of matrix metalloproteinase inhibitors (84 references, 63 patent references).
35. Rastelli G, Vianello P, Barlocco D, Costantino L, Del Corso A, Mura U: Structure-based design of an Inhibitor modeled at the substrate active site of aldose reductase. Bioorg Med Chem ie//(1997) 7:1897-1902.
36. von Itzstein M, Colman P: Design and synthesis of carbohydrate-based inhibitors of protein-carbohydrate interactions. CurrOpin StructBiol(1996) 6:703-709.
37. von Itzstein M, Thomson, RJ: Sialic acids and sialic acidrecognizing proteins: drug discovery targets and potential glycopharmaceuticals. Curr Med Chem (1997) 4:185-210. Comprehensive review on the structure-based design of neuraminidase inhibitors and other important aspects of sialic acid biology.
38. Wade RC: 'Flu' and structure-based drug design. Structure (1997)5:1139-1145.
39. Cianci C, Krystal M: Development of antivirals against influenza. Curr Opin Invest Drugs (1998) 7:149-165. Overview of different approaches to develop anti-influenza drugs; errors in formulas 4-6 (lacking nitrogen atom In the acetylamino group).
40. Montgomery JA, Niwas S, Rose JD, Secrist III, JA, Babu YS, Bugg CE, Erion MD, Guida WC, Ealick SE: Structurebased design of inhibitors of purine nucleoside phosphorylase. 1. 9-(aryf methyl) derivatives of 9deazaguanine. J Med Chem (1993) 36:55-69. Classical paper on the structure-based design of PNP inhibitors; highly interesting example of a non-additive structure-activity relationship due to changes in the binding mode of closely related analogs.
41. Montgomery JA: Structure-based drug design: inhibitors of purine nucleoside phosphorylase. Drug Design Discov (1994)11:289-305. Review on the structure-based design of PNP inhibitors (compare with [39"]).
42. Jackson RC: Contributions of protein structure-based drug design to cancer chemotherapy. Seminars in Oncology (1997) 24:164-172.
43. Morris PE, Montgomery JA: Inhibitors of the enzyme purine nucleoside phosphorylase. Exp Opin Ther Patents (1998)8:283-299. Review on recent developments in PNP inhibitor design (55 references, 33 patent references).
44. Arnold E, Das K, Ding J, Yadav PNS, Hsiou Y, Boyer PL, Hughes SH: Targeting HIV reverse transcriptase for antiAIDS drug design: structural and biological consideration for chemotherapeutic strategies. Drug Design Discov (1996) 13:29-47
45. Jones TR, Webber SE, Vamey MD, Reddy MR, Lewis KK, Kathardekar V, Mazdiyashni H, Deal J, Nguyen D, Welsh KM, Webber S, Johnston A, Matthews DA, Smith WW, Janson CA, Bacquet RJ, Howland EF, Booth CLJ, Herrmann SM, Ward RW, White J, Bartlett CA, Morse CA: Structure-based design of substituted diphenyl sulfones and surfoxides as lipophilic inhibitors of thymidylate synthase. J Med Chem (1997) 40:677-683.
46. Costi MP: Thymldylate synthase inhibition - a structurebased rationale for drug design. Med Res Rev (1998) 18:21-42.
47. Li R, Chen X, Gong B, Selzer PM, Li Z, Davidson E, Kurzban G, Miller RE, Nuzum EO, McKerrow JH, Fletterick RJ, Gillmor SA, Craik CS, Kuntz ID, Cohen FE, Kenyon GL: Structurebased design of parasitic protease Inhibitors. Bioorg Med Chem (1996) 4:1421-1427.
48. Navia MA: Protein-drug complexes important for immunoregulation and organ transplantation. Curr Opin Struct Bio/ (1996) 6:838-847.
49. De Lombaert S, Châtelain RE, Fink ÇA, Trapani AJ: Design and pharmacology of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Curr Pharm Des (1996) 2:443-462.
50. Yeng AY, De Lombaert S: Endothelin converting enzyme inhibitors. Curr Pharm Des (1997) 3:597-614.
51. Jeng AY: Therapeutic potential of endotheiin converting enzyme inhibitors. Exp Opin TrierPatents(1997) 7:1283-1295.
52. Traxler PM: Protein tyrosine kinase inhibitors in cancer treatment. Exp Opin Ther Patents (1997) 7:571 -588. Structure-based design of PTKinhibitors, starting from a pharmacophore model of the ATP-binding site of the EGF-receplor tyrosine kinase.
53. Hong H, Neamati N, Wang S, Nicklaus MC, Mazumder A, Zhao H, Burke Jr TR, Pommier Y, Milne GWA: Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem (1997) 40:930-936.
54. Samanen J: GPIIb/Illa antagonists, Annu Rep Med Chem (1996)31:91-100.
55. Engleman VW, Kellogg MS, Rogers TE: Cell adhesion Integrins as pharmaceutical targets. Annu Rep Med Chem (1996)31:191-200.
56. Giannis A, Rübsam F: Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: new drugs In cancer therapy. Angew Chem Int Ed £/7p/(1997) 36:588-590.
57. Haubner R, Finsinger D, Kessler H: Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the α,β, integrin for a new cancer therapy. Angew Chem Int Ed Engl(1997) 36:1375-1389. Review with special emphasis on NMR conformational analyses of cyclic pentapeptides (231 references).
58. Mousa SA, Cheresh DA: Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications. Drug Discovery Today (1997) 2:187199.
59. Vondrasek J, van Buskirk CP, Wlodawer A: Database of three-dimensional structures of HIV proteinases. Nature Strutr/ (1997)4:8. A public domain database of HIV protease-inhibitor complex 3D structures, including several entries not yet deposited in the Brookhaven PDB, is available underhttpMvww-fbsc.ncifcrf.gov/HIVdb.
60. Lam PYS, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN, Chang CH, Weber PC, Jackson DA, Sharpe TR, EricksonViitanen S: Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 263:380-384. Classical paper on the structure-based design of a new type of HIV protease inhibitors.
61. Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, Bacheler LT: Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem (1997) 40:181-191.
62. De Lucca QV, Liang J, Aldrich PE, Calabrese J, Cordova B, Klabe RM, Rayner MM, Chang CH: Design, synthesis and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors. J Med Chem (1997) 40:1707-1719.
63. Ganesh V, Lee AY, Clardy J, Tulinsky A: Comparison of the structures of the cyclotheonamide A complexes of human α-thrombin and bovine β-trypsin. Protein Sei (1996)5:825-35.
64. Tucker TJ, Lumma WC, Mulichak AM, Chen 2, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC: Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem (1997) 40:830-832.
65. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD, Cook JJ, Holahan MA, Stranieri MT, Lynch Jr JJ, Lin JH, Chen IW, Vastag K, Naylor-Olsen AM, Vacca JP: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecar-boxyl)propyl trans-4aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem (1998) 41:401 -406. Solid phase synthesis of a structurally diverse set of 200 amides selected from > 2,200 acid components.
66. Feng DM, Gardell SJ, Lewis SD, Bock MG, Chen 2, Freidinger RM, Naylor-Olsen AM, Ramjit HG, Woltmann R, Baskin EP, Lynch JJ, Lucas R, Shafer JA, Dancheck KB, Chen IW, Mao SS, Krueger JA, Hare TR, Mulichak AM, Vacca JP: Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J Med Chem (1997)40:3726-3733.
67. Lumma Jr WC, Witherup KM, Tucker TJ, Brady SF, Sisko JT, Naylor-Olsen AM, Lewis SD, Lucas BJ, Vacca JP: Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J Med Chem (1998) 41:1011-1013.
68. Sanderson PEJ, Dyer DL, Naylor-Olsen AM, Vacca JP, Gardell SJ, Lewis SD, Lucas Jr BJ, Lyle EA, Lynch Jr JJ, Mulichak AM: L-373,890, an achiral, noncovalent, subnanomolar thrombin inhibitor. Bioorg Med Chem Lett (1997)7:1497-1500.
69. a. Merck & Co Inc (Sanderson PE, Naylor-Olsen AM, Dyer DL, Vacca JP, Isaacs RCA, Dorsey BD, Praley ME) WO09701338(1995).
70. b. Pyridinone-thrombin inhibitors. Exp Opin Ther Patents (1997)7:651-654.
71. Sanderson PEJ: The development of L-374,087, a selective, efficacious, orally bioavailable non-covalent thrombin inhibitor. 214th ACS Meeting, Las Vegas, US (1997):MEDI114.
72. a. Kim S, Hwang SY, Kim YK, Yun M, Oh YS, Rational design of selective thrombin inhibitors. Bioorg Med Chem Lett (1997) 7:769-774.
73. b. Oh YS, Yun M, Hwang SY, Hong S, Shin Y, Lee K, Yoon KH, Yoo YJ, Kim DS, Lee SH, Lee YH, Park HD, Lee CH, Lee SK, Kim S: Discovery of LB30057, a benzamidrazonebased selective oral thrombin inhibitor. Bioorg Med Chem Lett (1998) 8:631 -634.
74. Obst U, Banner DW, Weber L, Diederich F: Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. Chem Biol (1997) 4:287295-De novo design of a nanomolar thrombin inhibitor in three design cycles.
75. von Itzslein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Phan TV, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363:418-423. Classical paper on the structure-based design of the first highly potent neuraminidase inhibitor.
76. von Itzstein M, Dyason JC, Oliver SW, White HF, Wu WY, Kok GB, Pegg MS: A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. JMed Chem (1996) 39:388-391.
77. Chanel P, Babu YS, Bantia S, Chu N, Cole LB, Kolian PL, Laver WG, Montgomery JA, Palhak VP, Petty SL, Shrout DP, Walsh DA, Walsh GM: Design and synthesis of benzole acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J Meet Chem (1997) 40:4030-4052.
78. Kim CU, Lew W, Williams MA, LJu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC: Influenza neuraminidase inhibitors possessing a novel Hydrophobie interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem 5oc(1997) 119:681-690. Structure-based design of a neuraminidase inhibitor with significantly impro ved pharmacokinetic properties.
79. Höltje HD, Folkers G: Molecular Modeling. Basic principles and applications. VCH, Weinheim (1996). Application-oriented text book with special emphasis on small molecule modeling, pharmacophore generation, protein and ligandprotein complex modeling.
80. Keenan RM, Miller WH, Kwon C, All FE, Callahan JF, Calvo RR, Hwang SM, Kopple KD, Peishoff CE, Samanen JM, Wong AS, Yuan CK, Huffman WF: Discovery of potent nonpeptide vrtronectin receptor (α,β,) antagonists. J Med Chem (1997) 40:2289-2292.
81. Samanen JM, Ali FE, Barton LS, Bondinell WE, Burgess JL, Callahan JF, Calvo RR, Chen W, Chen L, Erhard K, Feuerstein G, Heys R, Hwang SM, Jakas DR, Keenan RM, Ku TW, Kwon C, Lee CP, Miller WH, Newlander KA, Nichols A, Parker M, Peishoff CE, Rhodes G, Ross S, Shu A, Simpson R, Takata D, Yellin TO, Uzsinskas I, Venslavsky JW, Yuan CK, Huffman WF: Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/llla integrin antagonists. J Med Chem (1990) 39:4867-4870.
82. Graul AI: The year's new drugs. Drug News Perspect (1998)11:15-32. An historical and research perspective on the 56 new drugs that reached their first markets in 1997.